BOSTON — A study published in the British Medical Journal suggests that the rate of drug-induced acute hepatitis C (CoC) is falling, reversing a decline that has been driven by a shortage of anti-coagulants.
The study, by the British National Institute for Health Research, looked at the treatment of 12,000 CoC patients who had been diagnosed with acute hepatitis for at least one year and found that the proportion of patients who responded to treatment with a CoC drug had dropped from 62% to 46%.
The results are expected to be presented at the annual meeting of the American College of Physicians (ACP) on Thursday.
The decline in CoC treatment has been attributed to a number of factors, including better drugs and improved diagnostics.
In the study, which was funded by the National Institutes of Health, doctors found that drug-treated CoC had a 50% reduced chance of being re-infected with CoC-19.
This is a very important finding because it suggests that, although there may be many other factors at play, there is now a clear and consistent pattern of increased drug-related re-colonization of CoC, Dr. David Wootton, a co-author of the study and an assistant professor at the Department of Biomedical Sciences at the University of Cambridge, told ABC News.
CoC patients were less likely to receive a course of antihistamines than patients without CoC.
Other drugs were associated with a 50%-to-60% drop in the chance of having a coagulant re-incubate.
Dr. Woot, who was not involved in the study when it was published, told LiveScience that there was an increase in drug-resistant strains of CoH3CoC that are associated with increased re-coverage, but that this was not an indication for drug resistance.
In the United States, there have been reports of some patients receiving a treatment that causes a recurrence of CoP, but the majority of CoE cases that have been diagnosed are caused by CoH4, Dr Woot said.